GOGA LAB
  • Home
  • Research
  • Publications
  • People
  • Andrei Goga
  • Contact
  • News
  • Sushi Time
  • Home
  • Research
  • Publications
  • People
  • Andrei Goga
  • Contact
  • News
  • Sushi Time
Search by typing & pressing enter

YOUR CART

Picture
Andrei Goga is a basic investigator as well as a medical oncologist whose lab is focused on studies of oncogene function and the identification of new therapeutic strategies to target currently undrugable cancers and to eliminate metastasis.  

Much of our work is focused on aggressive forms of cancer, such as receptor triple-negative breast cancer, oral, head and neck, liver and lung cancers. 

Dr. Goga has received scholar awards from the
​Susan G. Komen Foundation, the Leukemia Lymphoma Society, and a CDMRP Breast Cancer Research Program - Era of Hope Award.  
Andrei Goga

Professor, Dept. Cell & Tissue Biology 
                    and Dept. of Medicine, Heme / Onc.

Member UCSF Biomedical Sciences and Tetrad Graduate Programs


UCSF Gazarian Presidential Chair

Co-Director, UCSF Oral, Head and Neck Research Group

Attending Physician - UCSF Breast Oncology Program

B.S., University of California, Los Angeles

M.D., University of California, Los Angeles

Ph.D., University of California, Los Angeles, Molecular Biology
   Mentor: Owen N. Witte, M.D.

Residency, Internal Medicine, UCSF

Fellowship, Medical Oncology, UCSF

Post-Doctoral Fellow, UCSF
   Mentors: J. Michael Bishop, M.D. and David Morgan, PhD


Current Research Support:
NIH / NCI
Atwater Foundation
Breast Cancer Research Foundation
Gazarian Family Foundation
CDMRP BCRP


Prior Research Funding:
Program in Breakthrough Biological Research (PBBR)
V- Foundation
Leukemia, Lymphoma Society (LLS)
Gallo Family Foundation
ACS Pilot Award

Selected Publications (click title for PDF) 

Review: In vivo Reprogramming of Cancer Metabolism by MYC.
Camarda R, Williams J, Goga A.
Front Cell Dev Biol. 2017 Apr 11;5:35.

Review:  Taking on Challenging Targets: Making MYC Druggable
Dai Horiuchi, PhD, Brittany Anderton, BS, and Andrei Goga, MD, PhD
2014 ASCO EDUCATIONAL BOOK | asco.org/edbook

MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer.
Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, Nomura DK, Goga A.
EMBO Rep. 2017 Apr;18(4):569-585.


PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A.
Nature Medicine 2016 Nov;22(11):1321-1329. 

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A 
Nature Medicine, 2016 Apr;22(4):427-32.

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells.
Lawson DA, Bhakta N, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A, Werb Z 
Nature, 2015 Oct 1;526(7571):131-5.


CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.
Huskey NE, Guo T, Evason KJ, Momcilovic O, Pardo D, Creasman KJ, Judson RL, Blelloch R, Oakes SA, Hebrok M, Goga A.
Stem Cell Reports. 2015 Mar 10;4(3):374-89.


MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A 
The Journal of Experimental Medicine 2012 Apr 9;209(4):679-96.


miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A
Nature Medicine, 2010 Oct;16(10):1134-40.


Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S.
Cancer Discovery. 2015 Feb;5(2):154-67.


MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer.
Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A.
Hepatology. 2014 Jan;59(1):202-15.

13C-Pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. 

Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ, Kurhanewicz J, Vigneron DB, Goga A.
Cell Metabolism 2011 Jul 6;14(1):131-42.